GlobeNewswire·Oct 29, 2026, 8:00 AM ET

MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide

MIRA

MIRA Pharmaceuticals announced initial positive proof-of-concept results for its investigational oral drug candidate SKNY-1 from an exploratory pilot study in diet-induced obese mice.
Oral SKNY-1 produced statistically significant reductions in body weight & fat mass compared with vehicle-treated controls.
Weight reduction occurred without a statistically significant decrease in food consumption, suggesting a potential role for energy expenditure rather than appetite suppression.
SKNY-1-treated mice showed no statistically significant loss of lean mass at Day 14, whereas semaglutide-treated mice demonstrated statistically significant lean-mass loss.
Following treatment discontinuation, SKNY-1-treated mice experienced slow & limited weight regain, while semaglutide-treated mice experienced rapid & substantial weight rebound accompanied by increased food consumption.
The study identified three key differentiation areas from semaglutide: effects on food intake, lean-mass outcomes, & weight regain after cessation.
Findings indicate SKNY-1 may influence metabolic pathways related to energy utilization or expenditure rather than relying primarily on appetite suppression.
MIRA plans to advance SKNY-1 through longer-term preclinical studies to directly measure energy expenditure & further characterize body composition & weight regulation effects.
SKNY-1 is a cannabinoid analog currently under IND-enabling development, chemistry, manufacturing & controls (CMC) efforts, & the U.S. Drug Enforcement Administration has determined it is not a controlled substance.